Zoe Adjei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zoe Adjei has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Carl J. Fichtenbaum
Professor of Clinical Medicine, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA
1 shared publicationDimple C. Patel
HIV Clinical Pharmacy Specialist, Department of Pharmacy, University of Cincinnati Health, Cincinnati, OH, USA
1 shared publicationKelli Williams
Associate Professor of Medicine, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA
1 shared publication- Marisa Brizzi
UC Health, Cincinnati, OH, USA
1 shared publication Tracy L. Cable
Assistant Professor of Medicine, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA
1 shared publication
Latest Publications
- Open Access
- 5 December 2024
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 52 (12)
Heavily treatment-experienced patients with HIV: are new mechanisms of action enough?
Antiretroviral (ARV) drug resistance poses a threat to ending the HIV epidemic. As the rates of integrase resistance continue to increase globally, the availability of options for HIV treatment becomes limited. Heavily treatment-experienced (HTE) people with HIV (PWH) are limited to two or fewer available fully active ARV classes and are more likely to have an AIDS-defining event. Appropriate identification and management of HTE PWH is crucial to improving patient outcomes and reducing the future spread of drug-resistant HIV. As treatment options become more limited owing to drug resistance, the availability of more potent drugs with a marked increase in virologic suppression is needed in the current ART era. The purpose of this narrative review is to review the identification of HTE PWH, novel mechanisms of resistance, and management of HTE PWH in resource-rich and resource-limited settings using novel ARVs and combination ART.
- 5 December 2024
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 52 (12)
Open AccessHeavily treatment-experienced patients with HIV: are new mechanisms of action enough?
Antiretroviral (ARV) drug resistance poses a threat to ending the HIV epidemic. As the rates of integrase resistance continue to increase globally, the availability of options for HIV treatment becomes limited. Heavily treatment-experienced (HTE) people with HIV (PWH) are limited to two or fewer available fully active ARV classes and are more likely to have an AIDS-defining event. Appropriate identification and management of HTE PWH is crucial to improving patient outcomes and reducing the future spread of drug-resistant HIV. As treatment options become more limited owing to drug resistance, the availability of more potent drugs with a marked increase in virologic suppression is needed in the current ART era. The purpose of this narrative review is to review the identification of HTE PWH, novel mechanisms of resistance, and management of HTE PWH in resource-rich and resource-limited settings using novel ARVs and combination ART.